Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study
Hübner IB, Scheibe DB, Marchezan J, Bücker J
Published in Clinical Neuropharmacology
Methodology
Randomized, crossover, double-blind, placebo-controlled pilot trial of citicoline in children aged 7-12 with ADHD, assessing attention, impulsivity and memory parameters.
Key Findings
No statistically significant difference was found between citicoline and placebo on any evaluated parameter; no adverse effects occurred.
Conclusions
Citicoline appears safe but showed no measurable cognitive benefit in this pilot trial.
Limitations
Pilot size, pediatric ADHD population, and short crossover design limit generalizability.
Supplements Studied
As a result, no statistically significant difference was noted between the use of citicoline and placebo in the evaluated parameters.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.